scholarly journals Effects of 4-Ethyl Resorcinol and 5-Methylresorcinol on Human Carbonic Anhydrase-I and Molecular Docking Study

Author(s):  
Pınar GÜLLER
2021 ◽  
pp. 152-160
Author(s):  
Thangavelu Ranjanamala ◽  
Vanmathiselvi Krishanan ◽  
Ramanatha Shreemaya ◽  
Sundarajan Nagarajan Rajeswari ◽  
Casimeer C Sangeetha ◽  
...  

Recent advances demonstrate phytochemicals to be a potent anticancer therapeutic agent as various anti-cancer targets. This study depicts the anti-cancer potential against certain crucial common cancer targets leading to cancer cell proliferation and survival. The main objective of this study is to study the anti-cancer potential of phloretin against certain cancer targets. Ligand analysis was performed and Phloretin was chosen as the experimental ligand and Bcl-2, NF Kappa B, Carbonic anhydrase I (CA-1), Inducible Nitric Oxide Synthase (iNOS), Endothelial Nitric oxide synthase (eNOS), Caspase 3, and Caspase 9 proteins were chosen as targets. Induced fit molecular docking was performed by the use of Glide 6.5 software (Schrodinger - 2015). The docked poses were further evaluated based on binding energy, Conformational changes, and the amino acid residues involved in the protein-ligand interaction. The docking results depicted that phloretin showed notable binding affinity especially with carbonic anhydrase I, ENOS, and INOS. It also showcased significant potential against Caspase 3 and NF Kappa, thereby showing its potential as an effective anti-cancer therapeutics. During this study, the Inhibitory potential of Phloretin was studied as a result of this molecular docking study. This Insilico study revealed the binding efficiency of phloretin against the aforementioned targets. In vitro analysis is required for further validation of this data.


2021 ◽  
Vol 14 (7) ◽  
pp. 693
Author(s):  
Kalyan K. Sethi ◽  
KM Abha Mishra ◽  
Saurabh M. Verma ◽  
Daniela Vullo ◽  
Fabrizio Carta ◽  
...  

New derivatives were synthesised by reaction of amino-containing aromatic sulphonamides with mono-, bi-, and tricyclic anhydrides. These sulphonamides were investigated as human carbonic anhydrases (hCAs, EC 4.2.1.1) I, II, IX, and XII inhibitors. hCA I was inhibited with inhibition constants (Kis) ranging from 49 to >10,000 nM. The physiologically dominant hCA II was significantly inhibited by most of the sulphonamide with the Kis ranging between 2.4 and 4515 nM. hCA IX and hCA XII were inhibited by these sulphonamides in the range of 9.7 to 7766 nM and 14 to 316 nM, respectively. The structure–activity relationships (SAR) are rationalised with the help of molecular docking studies.


Author(s):  
Heba M. Abo-salem ◽  
Khadiga M. Ahmed ◽  
Salwa El- Hallouty ◽  
Eslam R. El-sawy ◽  
Adel H. Mandour

<p><strong>Objective</strong>:<strong> </strong>The present work aimed to synthesize a new series of 1-methylsulphonyl-3-indolyl heterocycles and study their cytotoxic activity. In addition, we attempted to explore the mode of the interaction of anti-proliferative compounds with the active site of carbonic anhydrase IX (CA IX) theoretically <em>via</em> molecular docking study.</p><p><strong>Methods</strong>:<strong> </strong>Novel series of pyrazole, pyrimidine and triazole derivatives bearing 1-methylsulphonyl-1<em>H</em>-indole were prepared <em>via</em> a series of hetero cyclization reactions utilizing 3-(1-methylsulphonyl-1<em>H</em>-indol-3-yl)-1-(substituted phenyl)-1<em>H</em>-pyrazole-4-carboxaldehydes 3a-d and 3-chloro-3-(1-methylsulphonyl-1<em>H</em>-indol-3-yl)propenal (6) and evaluating their anti-proliferative activity. The structures of the newly synthesized compounds were confirmed by elemental analyses, IR, NMR and mass spectral data. In addition, molecular docking study of the most promising antiproliferative compounds against the active site of carbonic anhydrase IX (PDB ID: 4BCW) theoretically is discussed.</p><p><strong>Results</strong>:<strong> </strong>Compounds 5c, 7 and 12 revealed potent anti-proliferative effects against A-549 cancer cell line with IC<sub>50</sub> of 44.3, 17.2 and 38.7 µmol/l, respectively compared to the reference drug doxorubicin (IC<sub>50</sub> of 48.8 µmol/l). While compound <strong>5c</strong> was found to be highly active with IC<sub>50</sub> of 5.66 µmol/l against HCT-116 cancer cell line than doxorubicin (IC<sub>50</sub> of 65.00 µmol/l).</p><p><strong>Conclusion</strong>:<strong> </strong>Further work is recommended to confirm the inhibition of CA IX in a specific bioassay.</p>


2015 ◽  
Author(s):  
Manik Ghosh ◽  
Kamal Kant ◽  
Anoop Kumar ◽  
Padma Behera ◽  
Naresh Rangra ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document